CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Core Viewpoint - Nuvectis Pharma, Inc. reported its financial results for Q3 2025, highlighting advancements in its clinical programs, particularly the Phase 1b program for NXP900, and a significant increase in cash reserves due to a public offering. Financial Results - Cash and cash equivalents increased to $35.4 million as of September 30, 2025, from $18.5 million as of December 31, 2024, reflecting a $16.9 million increase primarily from a public offering and At-the-Market facility utilization [3] - The net loss for Q3 2025 was $7.5 million, up from $4.2 million in Q3 2024, with a $3.4 million increase attributed to a one-time $2.0 million milestone expense for NXP900 and $0.7 million for a clinical study [4] - Research and development expenses were $5.8 million for Q3 2025, compared to $2.8 million in Q3 2024, marking a $3.0 million increase [5] - General and administrative expenses rose to $2.0 million in Q3 2025 from $1.5 million in Q3 2024, an increase of $0.5 million [5] - Interest income for Q3 2025 was $0.3 million, up from $0.2 million in Q3 2024 [6] Clinical Development - The Phase 1b program for NXP900 has been initiated, with the single-agent study currently underway, aiming to demonstrate clinical efficacy in advanced cancers [7] - The Phase 1a dose escalation study for NXP900 was successfully completed, showing robust pharmacodynamic responses at clinically relevant doses [7] - A clinical drug-drug interaction study in healthy volunteers was also completed, supporting the strategy for combination therapy [7] - Poster presentations at the 2025 AACR-NCI-EORTC conference highlighted the emerging clinical profile of NXP900 and supported a biomarker-based patient selection strategy [7] Company Overview - Nuvectis Pharma, Inc. focuses on developing innovative precision medicines for serious unmet medical needs in oncology, with its lead program NXP900 being an oral small molecule inhibitor targeting SRC Family of Kinases [8] - The company is also considering next steps for NXP800, which has shown anti-cancer activity in specific ovarian cancer cases [8]